Analysis of glioma cell lines for amplification and overexpression of MDM2
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Recently, amplification of the gene encoding a p53 binding protein, MDM2, was determined in 8% of the cases constituting a large series of glioblastomas. Here we have utilized Southern blot analysis to examine 30 cell lines established from such tumors, and our investigation has revealed large increases in MDM2 gene dosage in two cases, one of which showed coamplification of the CDK4 gene that resides in close proximity to MDM2 in chromosomal region 12q13–14. Northern analysis demonstrated overexpression of MDM2 mRNA in the two cell lines with gene amplification, and overexpression of MDM2 protein was evident in each of these by immunohistochemical and Western blot analysis. Analysis of TP53 cDNAs revealed normal TP53 sequences in the cell lines with MDM2 amplification; these results are consistent with those of previous studies suggesting that MDM2 amplification occurs only in tumors expressing wild‐type p53. In total, these data suggest that MDM2 amplification in glioblastoma cell lines occurs at a frequency (6.7%) comparable to that determined in primary tumors; occurs in cell lines expressing wild‐type p53; and can involve the coamplification of additional genes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MDM2 amplifications occur in ~6.7% of all GBM cell lines, and only occur in cells that possess wild type p53 (wt-p53) [44].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [44]
Citations
Cites
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90021-2 · Cited by 46,426
A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity
Feinberg, A. P., & Vogelstein, B. (1983) · Analytical Biochemistry · doi:10.1016/0003-2697(83)90418-9 · Cited by 24,887
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., & Vogelstein, B. (1993) · Nature · doi:10.1038/362857a0 · Cited by 1,451
Wong, A. J., Bigner, S. H., Bigner, D. D., Kinzler, K. W., Hamilton, S. R., & Vogelstein, B. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.19.6899 · Cited by 849
Ekstrand, A. J., James, C. D., Cavenee, W. K., Seliger, B., Pettersson, R. F., & Collins, V. P. (1991) · PubMed · Cited by 719
Self-citationIdentification of an Amplified, Highly Expressed Gene in a Human Glioma
Kinzler, K. W., Bigner, S. H., Bigner, D. D., Trent, J. M., Law, M. L., O'Brien, S. J., Wong, A. J., & Vogelstein, B. (1987) · Science · doi:10.1126/science.3563490 · Cited by 681
Reifenberger, G., Liu, L., Ichimura, K., Schmidt, E., & Collins, V. P. (1993) · PubMed · Cited by 560
Self-citationp53 Mutation and MDM2 amplification in human soft tissue sarcomas.
Leach, F. S., Tokino, T., Meltzer, P. S., Burrell, M., Oliner, J., Smith, S., HILL, D. E., Sidransky, D., Kinzler, K. W., & Vogelstein, B. (1993) · PubMed · Cited by 533
Cited by
The MDM2 gene amplification database
Momand, J. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.15.3453 · Cited by 982
Functions of the MDM2 oncoprotein
Freedman, D. A., Wu, L., & Levine, A. J. (1999) · Cellular and Molecular Life Sciences CMLS · doi:10.1007/s000180050273 · Cited by 577
Gliomagenesis: genetic alterations and mouse models
Holland, E. C. (2001) · Nature Reviews Genetics · doi:10.1038/35052535 · Cited by 461
The p53 Pathway in Glioblastoma
Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., et al. (2018) · Cancers · doi:10.3390/cancers10090297 · Cited by 440
Weber, R. G., Boström, J., Wolter, M., Baudis, M., Collins, V. P., Reifenberger, G., & Lichter, P. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.26.14719 · Cited by 407
Self-citationThe Pathobiology of Glioma Tumors
Gladson, C. L., Prayson, R. A., & Liu, W. M. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102109 · Cited by 254
The Role of MDM2 Amplification and Overexpression in Tumorigenesis
Oliner, J. D., Saiki, A. Y., & Caenepeel, S. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026336 · Cited by 246
“…the T/T genotype (Bond et al. 2004), but a closer look at this result revealed that much of this difference was driven by a single G/G-genotype cell line (CCF-STTG1) reported to harbor an elevated MDM2 CN, ranging from 18.7 to 52 copies per cell (He et al. 1994; Cancer Cell Line Encyclopedia 2015).”
BackgroundInfluentialContrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR
Pandita, A., Aldape, K. D., Zadeh, G., Guha, A., & James, C. D. (2004) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.10300 · Cited by 211
Self-citationReifenberger, G., Ichimura, K., REIFENBERGER, J., ELKAHLOUN, A. G., Meltzer, P. S., & Collins, V. P. (1996) · PubMed · Cited by 192
Self-citationSung, T., Miller, D. C., Hayes, R. L., Alonso, M., Yee, H., & Newcomb, E. W. (2000) · Brain Pathology · doi:10.1111/j.1750-3639.2000.tb00258.x · Cited by 169
Momand, J., & Zambetti, G. P. (1997) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(19970301)64:3<343::aid-jcb1>3.0.co;2-v · Cited by 168
MicroRNAs/TP53 feedback circuitry in glioblastoma multiforme
Suh, S.-S., Yoo, J. Y., Nuovo, G. J., Jeon, Y.-J., Kim, S., Lee, T. J., Kim, T., Bakàcs, A., Alder, H., Kaur, B., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202465109 · Cited by 143
Characterization of p53 and p21 Functional Interactions in Glioma Cells en Route to Apoptosis
Gomez‐Manzano, C., Fueyo-Margareto, J., Kyritsis, A. P., Steck, P. A., Levin, V. A., Yung, W. K. A., & McDonnell, T. J. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.14.1036 · Cited by 142
Freedman, D. A., & Levine, A. J. (1999) · PubMed · Cited by 140
Advances in the genetics of glioblastoma: are we reaching critical mass?
Purow, B. W., & Schiff, D. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.96 · Cited by 130
The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells
Johannessen, T.-C. A., Prestegarden, L., Grudic, A., Hegi, M. E., Tysnes, B. B., & Bjerkvig, R. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos301 · Cited by 109
Rainov, N. G., Dobberstein, K.-U., Bahn, H., Holzhausen, H.-J., Lautenschläger, C., Heidecke, V., & Burkert, W. L. (1997) · Journal of Neuro-Oncology · doi:10.1023/a:1005841520514 · Cited by 98
MDM2 Protein Overexpression Promotes Proliferation and Survival of Multiple Myeloma Cells
Teoh, G., Urashima, M., Ogata, A., Chauhan, D., DeCaprio, J. A., Treon, S. P., Schlossman, R. L., & Anderson, K. C. (1997) · Blood · doi:10.1182/blood.v90.5.1982 · Cited by 96
Molecular Mechanisms in Gliomagenesis
Hulleman, E., & Helin, K. (2005) · Advances in cancer research · doi:10.1016/s0065-230x(05)94001-3 · Cited by 92
Altered molecular pathways in gliomas: An overview of clinically relevant issues
Rao, R. D., & James, C. D. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.07.002 · Cited by 90
Self-citationFrequent In activation of CDKN2A and Rare Mutation of TP53 in PCNSL
Cobbers, J. M. J. L., Wolter, M., REIFENBERGER, J., Ring, G. U., Jessen, F., An, H., Niederacher, D., Schmidt, E., Ichimura, K., Floeth, F. W., et al. (1998) · Brain Pathology · doi:10.1111/j.1750-3639.1998.tb00152.x · Cited by 82
Self-citationHuman glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor
Costa, B., Bendinelli, S., Gabelloni, P., Da Pozzo, E., Daniele, S., Scatena, F., Vanacore, R., Campiglia, P., Bertamino, A., Gomez-Monterrey, I., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072281 · Cited by 79
“The cumulative evidence of aberrantly increased activity of the primary p53 inhibitor MDM2 in GBM [11,12] prompted us to examine the effects of targeted inhibition of the MDM2-p53 interaction by the spiro-oxindole analogue ISA27, a recently described smallmolecule inhibitor of MDM2 [26].”
BackgroundAnalysis of the p53 and MDM‐2 gene in acute myeloid leukemia
Seliger, B., Papadileris, S., Vogel, D., Hess, G., Brendel, C., Störkel, S., örtel, J., Kolbe, K., Huber, C., Huhn, D., et al. (1996) · European Journal of Haematology · doi:10.1111/j.1600-0609.1996.tb01369.x · Cited by 55
Kanamori, M., Kon, H., Nobukuni, T., Nomura, S., Sugano, K., Mashiyama, S., Kumabe, T., Yoshimoto, T., Meuth, M., Sekiya, T., et al. (2000) · Oncogene · doi:10.1038/sj.onc.1203454 · Cited by 46
Saha, G., Sarkar, S., Mohanta, P. S., Kumar, K., Chakrabarti, S., Basu, M., & Ghosh, M. K. (2022) · Oncogene · doi:10.1038/s41388-022-02486-5 · Cited by 44
Genetic and signaling pathway alterations in glioblastoma relevance to novel targeted therapies
James, C. D. (2003) · Frontiers in bioscience · doi:10.2741/897 · Cited by 44
Self-citationCerrato, J. A., Yung, W. K. A., & Liu, T.-J. (2001) · Neuro-Oncology · doi:10.1093/neuonc/3.2.113 · Cited by 39
Kulkarni, D. A., Vázquez, A., Haffty, B. G., Bandera, E. V., Hu, W., Sun, Y., Toppmeyer, D., Levine, A. J., & Hirshfield, K. M. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp224 · Cited by 36
Molecular biology of malignant gliomas
Belda-Iniesta, C., de Castro, J., Sáenz, E. C., Guerrero, P. C., Perona, R., & Barón, M. G. (2006) · Clinical & Translational Oncology · doi:10.1007/s12094-006-0033-9 · Cited by 34
Canute, G. W., Longo, S. L., Longo, J. A., Shetler, M., Coyle, T., Winfield, J. A., & Hahn, P. J. (1998) · Neurosurgery · doi:10.1097/00006123-199803000-00031 · Cited by 31
Punganuru, S. R., Arutla, V., Zhao, W., Rajaei, M., Deokar, H. S., Zhang, R., Buolamwini, J. K., Srivenugopal, K. S., & Wang, W. (2020) · Cells · doi:10.3390/cells9071592 · Cited by 27
Senturk, J. C., Bohlman, S., & Manfredi, J. J. (2017) · Oncogene · doi:10.1038/onc.2017.229 · Cited by 22
Khatri, R. G., Navaratne, K., & Weil, R. J. (2008) · Journal of neurosurgery · doi:10.3171/jns/2008/109/11/0842 · Cited by 22
Chang, Y.-T. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i46.17476 · Cited by 20
Glioblastoma genetics: in rapid flux.
Purow, B. W., & Schiff, D. (2010) · PubMed · Cited by 19
Animal Models of Cell Cycle Dysregulation and the Pathogenesis of Gliomas
Holland, E. C. (2001) · Journal of Neuro-Oncology · doi:10.1023/a:1010609114564 · Cited by 17
MicroRNA-585 inhibits human glioma cell proliferation by directly targeting MDM2
Chen, W., Hong, L., Hou, C., Wang, Y., Wang, F., & Zhang, J. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01528-w · Cited by 14
Enhanced MDM2 Oncoprotein Expression in Soft Tissue Sarcoma: Several Possible Regulatory Mechanisms
Pollock, R. E., Lang, A., El‐Naggar, A. K., Radinsky, R., & Hung, M. (1997) · Sarcoma · doi:10.1080/13577149778443 · Cited by 10
Leucine-rich glioma inactivated 3: integrative analyses support its prognostic role in glioma
Kwon, N. S., Kim, D., & Yun, H. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s138912 · Cited by 9
The Molecular Biology of Brain Tumors
Barker, F. G., & Israel, M. A. (1995) · Neurologic Clinics · doi:10.1016/s0733-8619(18)30014-8 · Cited by 9
Pasdaran, A., Grice, I. D., & Hamedi, A. (2024) · Drug Development Research · doi:10.1002/ddr.22180 · Cited by 6
Lassman, A. B., & Holland, E. C. (2004) · Wiley eBooks · doi:10.1002/0471675067.mmc012 · Cited by 6
Zhang, W., & Fine, H. A. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-021-8_31 · Cited by 4
He, J., Olson, J. J., Ekstrand, A. J., Serbanescu, A., Yang, J. H., Offermann, M. K., & James, C. D. (1996) · Journal of neurosurgery · doi:10.3171/jns.1996.85.6.1085 · Cited by 4
Self-citationAli‐Osman, F. (2005) · Kluwer Academic Publishers eBooks · doi:10.1007/0-306-46861-1_11 · Cited by 3
Glioma Oncogenesis and Animal Models of Glioma Formation
Lyustikman, Y., & Lassman, A. B. (2006) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2006.09.005 · Cited by 3
Verma, S., & Pandey, A. K. (2021) · Network Modeling Analysis in Health Informatics and Bioinformatics · doi:10.1007/s13721-021-00286-7 · Cited by 3
Provenzale, J., & Friedman, A. H. (2006) · CRC Press eBooks · doi:10.1201/b13439-9 · Cited by 3
Fluorescent p53 helix mimetics pairing anticancer and bioimaging properties
Karmakar, S., Mallik, M., Sulava, S., Modi, U., Allu, S., Sangwan, S., Tothadi, S., Reddy, J. P., Vasita, R., Nangia, A. K., et al. (2025) · Biomaterials Science · doi:10.1039/d4bm01681e · Cited by 2
Brunelli, M., Eccher, A., Cima, L., Trippini, T., Pedron, S., Chilosi, M., Barbareschi, M., Scarpa, A., Pinna, G., Cabrini, G., et al. (2016) · Cancer Genetics · doi:10.1016/j.cancergen.2016.11.004 · Cited by 2
Rojas, M. L. (2011) · Digital Commons-TMC (Texas Medical Center) · Cited by 2
Gene Alterations in Glial Tumors
James, C. D. (1996) · Springer eBooks · doi:10.1007/978-4-431-66887-9_17
Self-citationFrequent and variable abnormalities in p14 tumor suppressor gene in glioma cell lines
Tanaka, Y., Zhang, S., Terasaki, H., Koga, H., 遠藤, 純., Usui, H., Washiyama, K., Kumanishi, T., Uematsu, Y., & Itakura, T. (2008) · Brain Tumor Pathology · doi:10.1007/s10014-007-0226-0
Genetic Profiling of Astrocytc Tumors
Sallinen, S. (2002) · Tampere University Institutional Repository (Tampere University)
Suh, S. (2012) · OhioLink ETD Center (Ohio Library and Information Network)
The role of Mdm2 in estrogen-mediated breast cancer cell proliferation
Brekman, A. (2011) · CUNY Academic Works (City University of New York)
mdm2 Amplification in NIH3T3L1 Preadipocytes Leads to Mdm2 Elevation in Terminal Adipogenesis
Litteral, V. (2008) · CORE Scholar (Wright State University)
Marmor, E. (1998) · TSpace (University of Toronto)
Mouse models for brain tumor therapy
Charles, N. A., Lassman, A. B., & Holland, E. C. (2011) · Elsevier eBooks · doi:10.1016/b978-0-443-06967-3.00017-x
Chen, W., Hong, L., Hou, C., Wang, Y., Wang, F., & Zhang, J. (2020) · Figshare · doi:10.6084/m9.figshare.13024349
Chen, W., Hong, L., Hou, C., Wang, Y., Wang, F., & Zhang, J. (2020) · Figshare · doi:10.6084/m9.figshare.13024352
Glioblastoma resistance to temozolomide : implication of α5β1 integrin and p53 signalling pathways
Sani, S. (2020) · theses.fr (ABES) · doi:10.70675/9566c585z0508z455bz9064z6bb61435b210
Crosstalk Between MDM2 and Akt Signaling Pathway in Oncogenesis.
Ramamoorthy, M. (2008) · VCU Scholars Compass (Virginia Commonwealth University) · doi:10.25772/b3wv-gq08
Metadata
- Authors
- He, J., Reifenberger, G., Liu, L., Collins, V. P., & James, C. D.
- Affiliations
- Emory University (US)
- Karolinska University Hospital (SE)
- Corresponding author
- James, C. David
- Venue
- Genes, Chromosomes and Cancer
- Publisher
- Wiley
- Published
- 1994-10
- Volume
- 11
- Issue
- 2
- Pages
- 91-96
- ISSN
- 1045-2257 (ISSN-L)
- 1098-2264
- OpenAlex
- W1976310780
- Cited by
- 56
- References
- 26
- Citations by year
- 2025: 1 · 2024: 1 · 2022: 1 · 2021: 1 · 2020: 5 · 2018: 1 · 2017: 2 · 2016: 2 · 2014: 1 · 2013: 1 · 2012: 2
- FWCI
- 1.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Genes Chromosomes and Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (7r01ca055728-06)
- National Cancer Institute (CA-55728)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- MDM2, gene amplification, glioblastoma, glioma cell lines, TP53, wild-type p53, MDM2 overexpression, p53-binding protein
- MeSH terms
- Gene Amplification, Glioblastoma, Humans, Immunohistochemistry, Nuclear Proteins, Proto-Oncogene Proteins, Tumor Cells, Cultured, Gene Expression Regulation, Neoplastic, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.